▲ +136.49% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for aTyr Pharma in the last 3 months. The average price target is $10.50, with a high forecast of $13.00 and a low forecast of $8.00. The average price target represents a 136.49% upside from the last price of $4.44.
The current consensus among 2 polled investment analysts is to buy stock in aTyr Pharma. This rating has held steady since February 2020, when it changed from a Hold consensus rating.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children's Hospital. It also has license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan; and a research collaboration with the Medical University of South Carolina to develop therapeutic antibodies that selectively target specific NRP2 isoforms. The company was founded in 2005 and is headquartered in San Diego, California.